Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Insulet Receives FDA Warning Letter Regarding Certain Insulin Pumps - Medical Product Outsourcing
Regulatory

Insulet Receives FDA Warning Letter Regarding Certain Insulin Pumps

Some lots reportedly did not conform to agency’s final acceptance criteria.

Insulet Corp. has received a warning letter from the U.S. Food and Drug Administration (FDA) concerning some of the company’s insulin pumps. The letter followed an inspection by the FDA of its headquarters facility in Billerica, Mass. in March. At that time, the FDA had issued a Form 483 and the company filed its response letter in April. A Form 483 is usually issued at the end of an inspection when the investigator finds out violation of prescribed standards.

The letter relates to the release of certain lots of the company’s Eros Omnipods that did not conform to the FDA’s final acceptance criteria, Insulet officials said in a regulatory filing. The lots were manufactured in mid-2013 and the first half of 2014.

Insulet reports that it does not expect the letter to have any adverse impact on its operations.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters